

JUBILANT DRUG DEVELOPMENT PTE LIMITED

Balance Sheet

As at 31st Mar		Notes No	2015	2015	2014	2014
			USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES						
Shareholders' Funds						
Share capital		1	2,547,001	127,332	2,547,001	127,332
Reserves & surplus		2	(74,910)	27,173	(61,728)	21,560
			2,472,091	154,506	2,485,273	148,893
Current liabilities						
Trade payables		3	12,707	794	4,722	283
Other current liabilities		4	159	10	159	10
			12,866	804	4,881	292
		Total				
			2,484,958	155,310	2,490,154	149,185
II. ASSETS						
Non-current investments		5	2,478,416	154,901	2,478,416	148,482
Long-term loans and advances		6	3,636	227	3,971	238
			2,482,052	155,128	2,482,387	148,720
Current assets						
Cash & bank balances		7	2,905	182	7,767	465
			2,905	182	7,767	465
		Total	2,484,958	155,310	2,490,154	149,185

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILANT DRUG DEVELOPMENT PTE LIMITED
Statement of Profit and Loss

For the year ended 31st March,		Notes No	2015	2015	2014	2014
Particulars			USD	INR (' In Thousands)	USD	INR (' In Thousands)
EXPENSES						
Other expenses	8		12,847	785	12,348	746
Total expenses			12,847	785	12,348	746
Profit before exceptional item and tax			(12,847)	(785)	(12,348)	(746)
Exceptional Items	9		335	21	54	3
Profit for the year			(13,182)	(806)	(12,402)	(750)

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILANT DRUG DEVELOPMENT PTE LIMITED

CASH FLOW STATEMENT

Cash flow Statement for the Year Ended	2015	2015	2014	2014
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
A. Cash flows from operating activities				
Net income before minority interest	(13,182)	(806)	(12,402)	(750)
Operating profit before working capital changes	(13,182)	(806)	(12,402)	(750)
Adjustments for :				
(Increase)/Decrease in trade and other receivables	335	20	54	3
Increase/(Decrease) in trade and other payables	7,985	488	(1,448)	(87)
Net cash inflow/(outflow) in course of operating activities	(4,862)	(297)	(13,796)	(834)
B. Cash flow arising from financing activities :				
Proceeds from issue of share capital(including share premium & net of share issue expenses)	-	-	20,000	1,208
Net cash inflow/(outflow) in course of financing activities	-	-	20,000	1,208
C. Foreign currency translation difference arising on consolidation				
		13	-	6
Net Increase in cash & cash equivalents (A+B+C)	(4,862)	(283)	6,205	380
Add: cash & cash equivalents at the beginning of year(including balance in dividend accounts)	7,767	465	1,562	85
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	2,905	182	7,767	465

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in Accounting Standard 3 (AS-3)- "Cash Flow Statements"

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

JUBILANT DRUG DEVELOPMENT PTE LIMITED
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL				
Authorized				
Equity Share Capital	-	-	-	-
	-	-	-	-
Issued & Subscribed				
2,547,001 equity shares of USD 1 each (Previous Year 2,54,7001 equity shares of USD 1 each)	2,547,001	127,332	2,547,001	127,332
	2,547,001	127,332	2,547,001	127,332
Paid up				
2,547,001 equity shares of USD 1 each (Previous Year 2,54,7001 equity shares of USD 1 each)	2,547,001	127,332	2,547,001	127,332
	-	-	-	-
	2,547,001	127,332	2,547,001	127,332

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shareholders holding more than 5% shares in the company

As at 31st March	2015	2015	2014	2014
Name of the shareholder	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd,-the Holding Company	2,547,001	100.00%	2,547,001	100.00%

4) The reconciliation of the number of shares outstanding as at beginning and at the end of reporting period

As at 31st March	2015	2015	2014	2014
Name of the shareholder	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Numbers of shares at the beginning	2,547,001	127,332	2,527,001	126,258
Add: Shares issued during the year	-	-	20,000	1,074
Numbers of shares at the end	2,547,001	127,332	2,547,001	127,332

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st March	2015	2014	2014	2014
Particulars	No.	'INR (' In Thousands)	No.	'INR (' In Thousands)
Jubilant Life Sciences (BVI) Ltd, British Virgin Islands-the Holding Company 25,47,001 equity shares of USD 1 each	2,547,001	127,332	2,547,001	127,332

JUBILANT DRUG DEVELOPMENT PTE LIMITED
Notes to the Financial Statements

As at 31st Mar	2015	2015	2014	2014
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Foreign Currency Translation Reserve Opening	-	24,702	-	-
Foreign Currency Translation Reserve During the Year	-	6,419	-	24,702
	-	31,121	-	24,702
Surplus as per P&L Account				
As per last Balance Sheet	-61,728	-3,142	-49,326	-2,392
Add: Net Profit after tax transferred from Statement of Profit and Loss	-13,182	-806	-12,402	-750
	-74,910	-3,948	-61,728	-3,142
	-74,910	27,173	-61,728	21,560
3. TRADE PAYABLES				
Trade payables-others	12,707	794	4,722	283
	12,707	794	4,722	283
4. OTHER CURRENT LIABILITIES				
Other payables	159	10	159	10
	159	10	159	10
5. NON CURRENT INVESTMENTS				
Investment in Subsidiary/Fellow Subsidiaries Companies				
Jubilant Chemsys Limited	2,076,349	129,772	2,076,349	124,394
1,999,766 Shares (Previous year 1,999,766 shares) of Rs. 10 each				
Jubilant Clinsys Limited	402,067	25,129	402,067	24,088
1,999,766 Shares (Previous year 1,999,766 shares) of Rs. 10 each				
	2,478,416	154,901	2,478,416	148,482
6. LONG TERM LOAN AND ADVANCES				
Security deposits	3,636	227	3,971	238
	3,636	227	3,971	238
7. CASH AND BANK BALANCES				
Balances with banks:				
- On current accounts	2,905	182	7,767	465
	2,905	182	7,767	465
8. OTHER EXPENSE				
Auditors Remuneration -As Auditors	4,016	245	3,824	231
Legal , professional & consultancy charges	8,811	539	8,224	497
Directors' sitting fees	-	-	159	10
Bank Charges	20	1	140	8
	12,847	785	12,348	746
9. EXCEPTIONAL ITEMS				
Foreign Exchange Gain/Loss	335	21	54	3
	335	21	54	3